Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Olanzapine for patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study
Autore:
Dursun, SM; Gardner, DM; Bird, DC; Flinn, J;
Indirizzi:
Dalhousie Univ, QEII Hlth Sci Ctr, Dept Psychiat, Psychopharmacol Unit, Halifax, NS B3H 2E2, Canada Dalhousie Univ Halifax NS Canada B3H 2E2 nit, Halifax, NS B3H 2E2, Canada Dalhousie Univ, Coll Pharm, Dept Psychiat, Halifax, NS B3H 2E2, Canada Dalhousie Univ Halifax NS Canada B3H 2E2 iat, Halifax, NS B3H 2E2, Canada QEII Hlth Serv Ctr, Mental Hlth Serv, Halifax, NS, Canada QEII Hlth Serv Ctr Halifax NS Canada ntal Hlth Serv, Halifax, NS, Canada
Titolo Testata:
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
fascicolo: 7, volume: 44, anno: 1999,
pagine: 701 - 704
SICI:
0706-7437(199909)44:7<701:OFPWTS>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
CLOZAPINE;
Keywords:
treatment-resistant schizophrenia; olanzapine; antipsychotics;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
9
Recensione:
Indirizzi per estratti:
Indirizzo: Dursun, SM Dalhousie Univ, QEII Hlth Sci Ctr, Dept Psychiat, Psychopharmacol Unit, 4083 AJLB,5909 Jubilee Rd, Halifax, NS B3H 2E2, Canada Dalhousie Univ 4083 AJLB,5909 Jubilee Rd Halifax NS Canada B3H 2E2
Citazione:
S.M. Dursun et al., "Olanzapine for patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study", CAN J PSY, 44(7), 1999, pp. 701-704

Abstract

Objective: This prospective, consecutive case-series outcome investigationevaluates the effectiveness olanzapine in 16 patients with treatment-resistant schizophrenia. Method: Treatment resistance was defined as nonresponsiveness to at least 3 antipsychotic drugs from at least 2 different chemical classes. A minimumbaseline score on the Brief Psychiatric Rating Scale (BPRS) of 45 was required for enrolment. Outcome evaluation measures included the BPRS, Global Assessment Scale (GAS), and Abnormal Involuntary Movement Scale (AIMS). Results: Subjects (n = 16) had a mean age of 40 years and mean duration ofillness of 16 years. Olanzapine treatment was initiated at 5 mg daily and was increased based on clinical judgement up to a maximum of 40 mg daily. Significant decreases in mean BPRS (P < 0.001) and GAS (P < 0.01) scores were observed at weeks 4, 8, 12, and 16, compared with baseline. Eight of 16 patients responded to olanzapine, as defined by a 20% decrease in BPRS scoreby week 16. Dyskinetic movements significantly increased at week 4 (P < 0.01) but did not differ from baseline at weeks 8 and 16. Conclusion: These results suggest that olanzapine at moderate to high doses may offer an effective treatment for a significant proportion of patientswith schizophrenia nonresponsive to multiple trials of conventional antipsychotics. A randomized controlled trial is encouraged to validate these findings, and comparative trials are required to determine when clinicians should consider this approach.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/11/20 alle ore 12:49:12